Evidence map›Paper›PMID 40881098›Full record

ArticleWorld journal of clinical pediatrics2025

Outcomes and adverse events following intra-arterial chemotherapy for retinoblastoma: A single center study in South India.

Abhishek Das, Kothapally Saiteja, Parag K Shah, Subramaniam Prema, Venkatapathy Narendran

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Abhishek DasDepartment of Pediatric Retina and Ocular Oncology, Postgraduate Institute of Ophthalmology, Aravind Eye Hospital, Coimbatore 641014, Tamil Nādu, India.
Kothapally SaitejaDepartment of General Ophthalmology, Aravind Eye Hospital, Coimbatore 641014, Tamil Nādu, India.
Parag K ShahDepartment of Pediatric Retina and Ocular Oncology, Postgraduate Institute of Ophthalmology, Aravind Eye Hospital, Coimbatore 641014, Tamil Nādu, India. drshahpk2002@yahoo.com.
Subramaniam PremaDepartment of Pediatric Retina and Ocular Oncology, Postgraduate Institute of Ophthalmology, Aravind Eye Hospital, Coimbatore 641014, Tamil Nādu, India.
Venkatapathy NarendranDepartment of Pediatric Retina and Ocular Oncology, Postgraduate Institute of Ophthalmology, Aravind Eye Hospital, Coimbatore 641014, Tamil Nādu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntra-arterial chemotherapy (IAC) has become a first-line standard treatment for retinoblastoma (RB). However, studies describing its adverse events are sparse, especially from the developing world. Our study described the outcomes and adverse events from a single center in South India.

aimTo describe the challenges, treatment outcomes, and complications of selective IAC for RB in Indian eyes.

methodsThis study was a single center, retrospective study that included 17 patients with RB who underwent IAC using melphalan (5/7.5 mg) and topotecan (1/2 mg) (

resultsOut of the 17 patients, 11 were diagnosed with unilateral RB and 6 were diagnosed with bilateral RB. The mean age at the time of diagnosis was 19.8 months. The mean interval between the first symptom and presentation was 6.5 months. IAC was employed as the primary (

conclusionIAC is an effective way to control RB and globe preservation. In the Indian context we encountered many challenges highlighting the importance of case selection. Further studies in India are required to thoroughly understand IAC as a treatment for RB.

Indexed as

Adverse eventsIndiaIntra-arterial chemotherapyRetinoblastomaTreatment outcomes

Identifiers

PMID40881098
PMCPMC12304904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.